Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02137239 · ClinicalTrials.gov registry record · Phase 2
Regimen Optimization Study
A Phase 2 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 2
- Development phase
- 58
- Enrollment target
NCT02137239 is a Phase 2 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 58 participants.
The verdict
NCT02137239, a Phase 2 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 58 participants
- Enrollment target
Study Summary
Patients who undergo a kidney transplant require prolonged therapy with drugs that suppress the immune system (called immunosuppressive regimens) to stop the immune system from attacking the transplanted kidney in order to limit damage to or the possibility of rejecting the transplanted kidney. The purpose of this study is to evaluate benefits and risks of two immunosuppressive regimens (belatacept with everolimus or tacrolimus with mycophenolate mofetil) following thymoglobulin induction and rapid corticosteroid withdrawal.
Interventions
- DRUG Thymoglobulin
- DRUG Belatacept
- DRUG Corticosteroids
- DRUG mycophenolate mofetil(MMF)
- DRUG Everolimus(EVL)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2015-12-31 |
| Est. Completion | 2019-05-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02137239
The ClinicalTrials.gov registry entry for NCT02137239 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 58 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Thymoglobulin is the first listed.
NCT02137239 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02137239 about?
NCT02137239 is a clinical study titled "Regimen Optimization Study". Patients who undergo a kidney transplant require prolonged therapy with drugs that suppress the immune system (called immunosuppressive regimens) to stop the immune system from attacking the transplanted kidney in order to limit damage to or the possibility of rejecting the transplanted kidney. The ...
What is the current status of trial NCT02137239?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 58 participants. The study started on 2015-12-31. Estimated completion is 2019-05-02.
What interventions are being tested in trial NCT02137239?
The interventions under investigation include: Thymoglobulin (DRUG), Belatacept (DRUG), Corticosteroids (DRUG), mycophenolate mofetil(MMF) (DRUG), Everolimus(EVL) (DRUG).
Who is sponsoring clinical trial NCT02137239?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.